Delivery Order SPE2DB22D3011-SPE2DB25FQ2UL
- Not listed
- The Defense Logistics Agency (DLA) awarded a $23,699.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with an ultimate completion date of August 19, 2025. This is a firm fixed price, non-set-aside contract awarded competitively on August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,677.38 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with performance in Conshohocken, Pennsylvania and completion targeted for September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $37,120.42 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania, will serve as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $70,857.49 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This firm fixed price, competitively awarded contract was executed on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the open competitive procurement process through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,168.81 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical supply delivery under AmerisourceBergen's broader federal contracting...
- The Defense Logistics Agency awarded a $10,359.88 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 16, 2025. The contract was competitively awarded with no set-aside designation and is structured as a firm fixed-price delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Enbrel 50 mg/mL syringes, valued at $9,158.68 with a firm fixed price structure. The contract has an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $18,364.76 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml syringes. This firm fixed price contract, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, represents a competitively awarded non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,778.84 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This non-set-aside, firm fixed price delivery order was awarded on September 4, 2025, with an ultimate completion date of September 5, 2025. Performance will occur at the vendor's location in Conshohocken, Pennsylvania. Enbrel is a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other inflammatory...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2ULDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,620.78 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed price contract was issued on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under a larger procurement vehicle supporting federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this delivery order as part of its extensive portfolio of federal medical procurement contracts with the DLA and related defense health systems. The company holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026, which serves as the primary vehicle enabling comprehensive global pharmaceutical support to military healthcare programs. Enbrel, a specialty medication used in the treatment of autoimmune conditions, represents the type of specialized pharmaceutical product the vendor routinely supplies to support military personnel and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.6k | 9/17/25 |